SCHEMBL17860787

SCHEMBL17860787

CC(C)(C)OC(=O)NCC[C@H](O)C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.57
IDO1 P14902 1/20 0.53
MAPT P10636 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.48
SLC1A3 P43003 1/20 0.47
SLC1A1 P43005 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RECQL P46063 1/20 0.46
HTT P42858 1/20 0.46
GAA P10253 1/20 0.46
CTSS P25774 1/20 0.46
NTSR1 P30989 1/20 0.46
PPARA Q07869 1/20 0.46
CTSL P07711 1/20 0.45
KLK7 P49862 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24593936 1.00 SYK (0.57) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL7941702 0.90 MAPT (0.55) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL17878734 0.86 SYK (0.56) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL4142820 0.85 SYK (0.55) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL24428751 0.85 SYK (0.55) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL13480455 0.84 SYK (0.66) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL16274170 0.84 SYK (0.63) SYKIDO1MAPTL3MBTL1POLB
SCHEMBL7429956 0.84 SYK (0.63) SYKIDO1MAPTL3MBTL1POLB
SCHEMBL15202883 0.84 SYK (0.64) SYKIDO1MAPTL3MBTL1LMNA
SCHEMBL5440929 0.82 SYK (0.64) SYKIDO1MAPTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233889-B1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-9771394-B2 Antimicrobial polymyxins for treatment of bacterial infections MICURX PHARMACEUTICALS, INC. (KY) 2017-09-26 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. 2016-06-30 US disclosed
WO-2016100578-A2 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185823-A1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS VIP, AQP1, PEF1 SYK 1484/4885IDO1 3657/4885MAPT 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.